TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02261727
Drug: Theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor
Study: NCT02261727
Drug: Placebo (for prednisone)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily~* Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily
Study: NCT02261727
Drug: Placebo (for Theophylline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)
Study: NCT03239821
Drug: Codeine Phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 58.8 mg codeïne phosphate
Study: NCT03239821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirupus Simplex
Study: NCT02057315
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of matching placebo over 3 bilateral applications.
Study: NCT03934450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
Study: NCT00207688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
Study: NCT01388738
Drug: L-Alpha glycerylphosphorylcholine
Normalized name: L-alpha-Glycerophosphorylcholine
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: choline alfoscerate IV 1000mg daily 10 days
Study: NCT00969449
Drug: Naprelan, (BAY H6689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of Naprelan 500 mg (2 tablets) under fasting conditions
Study: NCT02429440
Drug: Granulocyte Macrophage Colony Stimulating Factor
Normalized name: Granulocyte macrophage colony stimulating factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: intradermal
Study: NCT00397826
Drug: MK0733
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of Treatment: 12 Weeks
Study: NCT01952951
Drug: Capecitabine Oxaliplatin
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.
Study: NCT02911714
Drug: Lumason Contrast-Enhanced Ultrasound
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: In both arms, we will use Lumason to measure kidney allograft perfusion via contrast-enhanced ultrasound.
Study: NCT00016887
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02972255
Drug: RO7079901
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7079901 will be administered as per schedule described in individual arm.
Study: NCT01120496
Drug: 3% hypertonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
Study: NCT01120496
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
Study: NCT00457925
Drug: GSK221149A
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00840476
Drug: Meloxicam 15 mg Tablets
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 x 15 mg, single-dose fasting
Study: NCT02776488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of normal saline
Study: NCT00006366
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00909311
Drug: ABT-450
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, QD, 1 dose in each cross-over period
Study: NCT00835263
Drug: Lamictal®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Tablet
Study: NCT01789970
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.~Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.~Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Study: NCT01789970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.~Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
Study: NCT02112370
Drug: Ropivacaine with epinephrine injection
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.
Study: NCT03334175
Drug: Walnuts
Normalized name: WALNUTS,GRANULATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
Study: NCT01399580
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
Study: NCT01839344
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: An oral single dose of a solid, colored empty capsule.
Study: NCT00003035
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02925130
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral intake of a placebo drug
Study: NCT01447017
Drug: DPK-060
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPK-060 2% ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
Study: NCT01447017
Drug: Placebo for DPK-060 ear drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for DPK-060 ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
Study: NCT01612260
Drug: placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 granules t.i.d. po for 12 weeks
Study: NCT00578526
Drug: SU011248
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
Study: NCT00578526
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsule OD PO for 28 days then 14 days rest until disease progression
Study: NCT02127190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01576692
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy may include the following at the dosages shown below:~* cyclophosphamide: 400 mg/m\^2 IV days 1-5~* topotecan: 1.2 mg/m\^2 IV days 1-5~* temozolomide: 150 mg/m\^2 PO at least 1 hour before irinotecan~* irinotecan: 50 mg/m\^2 IV over 1 hour daily for 5 days~* carboplatin (AUC 8-dosing based on GFR), IV day 1 only~* ifosfamide: 2 g/m2 IV days 1-3~* etoposide: 100 mg/m2 days 1-3
Study: NCT01999803
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03978767
Drug: Ibuprofen 600 mg
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: NSAID pain medication to be used in the experimental bundle for postpartum analgesia
Study: NCT03978767
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAID analgesic to be used in the experimental bundle for postpartum analgesia in patients who underwent cesarean section
Study: NCT03978767
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesic medication to be used in both treatment arms
Study: NCT04898556
Drug: Prasterone 6.5 MG
Normalized name: prasterone 6.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose to be applied will be one Intrarosa ovule (Prasterone 6.5mg) a day before going to bed for 12 weeks.
Study: NCT03350217
Drug: Eleview
Normalized name: Eleview Submucosal Injectable Composition
Approvals — FDA: no, EMA: no, PMDA: no
Description: If a lesion in the colon is found to fit the description listed in the protocol, the subject will be randomized to Eleview or Hetastarch as the injectate solution for the procedure. The injectate solution is used, as needed, to aid in the resection of the target lesion.
Study: NCT00285805
Drug: response (sodium excretion) to amiloride infusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01496612
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00830362
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered once
Study: NCT01087645
Drug: NN9925 (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
Study: NCT01087645
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
Study: NCT01087645
Drug: NN9925 (oral)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
Study: NCT01087645
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomised to receive a single dose of placebo
Study: NCT00545662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
Study: NCT01028586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablets
Study: NCT01420744
Drug: 1% Human Albumin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.~Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.~Treatment will be administered over a 5-day period.~Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)
Study: NCT03702218
Drug: Direct Acting Antivirals
Normalized name: DIRECT ACTING ANTIVIRALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who are given organ transplants from donors that are Ab positive and NAT negative or Ab positive and NAT positive for Hepatitis C will be treated with direct acting antivirals after transplant if they become NAT+ for hepatitis C.~Interventions as follows.~Liver Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - Genotype 1-6~* Harvoni (ledipasvir/sofosbuvir) + Ribavirin - Genotypes 1, 4, 5, 6; GFR\>30~* Epclusa (sofosbuvir/velpatasvir) + Ribavirin - Genotypes 1-6; GFR\>30~Kidney Transplant:~• Combinations of choice:~* Mavyret (glecaprevir/pibrentasvir) - genotype 1-6~* Harvoni (sofosbuvir/ledipasvir) - genotype 1, 4; GFR\>30
Study: NCT01103713
Drug: Azithromycin plus chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
Study: NCT04378621
Drug: TNF-α inhibitor OR JAK inhibitor
Normalized name: Tumor necrosis factor alpha (TNF-alpha) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological anti-rheumatic treatment
Study: NCT01501253
Drug: CKD-828 2.5/40mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
Study: NCT01501253
Drug: CKD-828 2.5/80mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
Study: NCT00828659
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828659
Drug: Active Comparator #1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828659
Drug: Active Comparator #2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00828659
Drug: Active Comparator #3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03099486
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,
Study: NCT00374244
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: half of the subjects are randomized to placebo group
Study: NCT03280979
Drug: rescue regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
Study: NCT00584870
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral naproxen 500 mg twice daily for Weeks 1-12.
Study: NCT00584870
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
Study: NCT03216356
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: polyethylene glycol 3350 powder
Study: NCT03216356
Drug: Study Pill
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 250 mg DCS (derived from Seromycin 250 mg capsules) or polyethylene glycol 3350 powder
Study: NCT00727493
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
Study: NCT01169558
Drug: Fluoropyrimidine-based Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoropyrimidine-based chemotherapy administered according to standard of care.
Study: NCT00592111
Drug: COPP/ABV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 courses of COPP/ABV hybrid
Study: NCT00592111
Drug: COPP/ABV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 courses of COPP/ABV hybrid
Study: NCT03542669
Drug: 6B11-OCIK Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two infusions of 6B11-OCIK will be performed at each chemotherapy cycle (Day 3 an Day 7) during the first three cycles, while PBMC will be collected before each cycle (Day -12) during the first three cycles.
Study: NCT03542669
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be adminitered 4\~6 cycles of chemotherapy (Doxorubicin, 30 mg/m\^2 IV on Day 1 of every cycle)
Study: NCT00242554
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00484497
Drug: cyclamax
Normalized name: cyclamate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03398577
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer based randomization software will be used in order to randomize eligible consenting subjects to placebo or Dapagliflozin 10 mg treatment using a 1:2 ratio.
Study: NCT02436876
Drug: MBN-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBN-101 is a locally administered, anti-infective drug product
Study: NCT02995109
Drug: BAY987521
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code: Z11-004)
Study: NCT02995109
Drug: SPF Control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.
Study: NCT01447719
Drug: florbetapir F 18
Normalized name: Florbetapir F 18
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
Study: NCT02738606
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01881165
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02594358
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
Study: NCT01163435
Drug: sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
Study: NCT00843024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match
Study: NCT01466647
Drug: AXL1717
Approvals — FDA: no, EMA: no, PMDA: no
Description: A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
Study: NCT00640991
Drug: glulisine insulin, glargine insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion of glulisine, SC injection of glargine
Study: NCT03447353
Drug: Norco 10Mg-325Mg Tablet
Normalized name: Norco 10mg-325mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose on two of the four study visits, one in conjunction with 1mg alprazolam
Study: NCT03447353
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose on two of the four study visits, double dose on one of the four study visits
Study: NCT03355716
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: fentanyl (30.0 Mc)
Study: NCT04037891
Drug: rVA576
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: The first 3 patients selected for the study will be treated with the active drug in open-label.
Study: NCT04037891
Drug: rVA576
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 2: Sixteen patients will be randomised 1:1. between active and placebo and patients allocated to either group will receive the appropriate product throughout the trial.
Study: NCT04167670
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets administered orally.
Study: NCT05217472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Injection
Study: NCT05217472
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Injection
Study: NCT00462345
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
Study: NCT01373593
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03344393
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous normal saline infusion intraoperatively
Study: NCT02927626
Drug: Yang Yin Fu Zheng therapy
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yang Yin Fu Zheng is a Chinese herbal compound.
Study: NCT02927626
Drug: Routine medical care
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine medical care
Study: NCT02903108
Drug: SRP plus placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP followed by placebo gel placement into intrabony defect
Study: NCT00372983
Drug: NOV-205
Normalized name: Dallergy Reformulated Nov 2011
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01594762
Drug: Topical placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of treatment
Study: NCT00000329
Drug: Opioid-Related Disorders
Normalized name: DRUGS FOR ACID RELATED DISORDERS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01730469
Drug: AT1001 150 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT1001 150mg is available as a capsule
Study: NCT00533598
Drug: MK0557
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01265550
Drug: Desipramine
Normalized name: Desipramine
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
Study: NCT03638466
Drug: SPN-810
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of SPN-810 36 mg on neuronal brain activity, GABA and Glutamate levels and on the aggression score
Study: NCT03638466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of placebo on neuronal brain activity, GABA and Glutamate levels and on the aggression score
Study: NCT03409835
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 2 ml is administered after induction of general anesthesia.
Study: NCT00115102
Drug: fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes